Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anaptysbio (ANAB) EBT (2016 - 2025)

Anaptysbio's EBT history spans 10 years, with the latest figure at $62.8 million for Q4 2025.

  • For Q4 2025, EBT rose 388.04% year-over-year to $62.8 million; the TTM value through Sep 2025 reached -$84.6 million, up 48.94%, while the annual FY2024 figure was -$145.2 million, 11.22% up from the prior year.
  • EBT reached $62.8 million in Q4 2025 per ANAB's latest filing, up from $15.1 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $62.8 million in Q4 2025 to a low of -$46.7 million in Q2 2024.
  • Average EBT over 5 years is -$23.4 million, with a median of -$31.2 million recorded in 2021.
  • Peak YoY movement for EBT: crashed 6121.91% in 2022, then soared 388.04% in 2025.
  • A 5-year view of EBT shows it stood at -$31.1 million in 2021, then rose by 28.8% to -$22.1 million in 2022, then crashed by 90.53% to -$42.2 million in 2023, then soared by 48.33% to -$21.8 million in 2024, then skyrocketed by 388.04% to $62.8 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's EBT are $62.8 million (Q4 2025), $15.1 million (Q3 2025), and -$38.6 million (Q2 2025).